Morimitus H
Department of Urology, School of Medicine, Nagasaki University, Japan.
Nihon Hinyokika Gakkai Zasshi. 1990 Feb;81(2):215-20. doi: 10.5980/jpnjurol1989.81.215.
We suspect a difference between the effective rate of human tumor clonogenic assay (HTCA) and that of clinical chemotherapy against renal cell carcinoma. We investigated the sensitivity of ACHN, the cell line of renal cell carcinoma, and its colony forming cells (dividing cells) obtained on double soft agar against vincristine sulphate (VCR). In addition, PC-3, a cell line of prostatic carcinoma, and HeLa, cell line of cervicar carcinoma, were investigated. We obtained the results that each colony forming cells had higher sensitivity than each parent cells against VCR in the growth activities and the DNA synthesis measured by the uptake of 3H-thymidine. Because the cells targeted by HTCA are dividing cells, they are oversensitive compared with the true sensitivity of tumors.
我们怀疑人肿瘤克隆形成试验(HTCA)的有效率与临床化疗对肾细胞癌的有效率之间存在差异。我们研究了肾细胞癌细胞系ACHN及其在双层软琼脂上获得的集落形成细胞(分裂细胞)对硫酸长春新碱(VCR)的敏感性。此外,还研究了前列腺癌细胞系PC-3和子宫颈癌细胞系HeLa。我们得到的结果是,在通过3H-胸腺嘧啶核苷摄取测量的生长活性和DNA合成方面,每个集落形成细胞对VCR的敏感性均高于每个亲本细胞。由于HTCA靶向的细胞是分裂细胞,因此与肿瘤的真实敏感性相比,它们过于敏感。